THE RIGHT TRIALS, PATIENTS, AND PLACES FOR MEANINGFUL ONCOLOGY RESEARCH

Innovative research requires an ingenious mediation of patient and program needs. Worldwide excels in the essentials while taking a vanguard approach to the latest in preclinical science and study design.

TEAM BACKGROUND MAKES A DIFFERENCE

Many of our oncology team members have spent time conducting research or clinical care themselves, giving them an edge in overcoming the operational and patient-centered challenges that often plague trials conducted in this space. From preclinical and dose escalation expertise to regulatory approval, we are just the right size to offer accessible, nimble attention and a bevy of the industry’s top talent. That’s why Worldwide is rated a top performer for staff, delivery, budget and loyalty across phase I-III CRO services by Industry Standard Research.

ALAEDDIN HOMSI, MS, BS

EXECUTIVE DIRECTOR, PROJECT MANAGEMENT, ONCOLOGY & HEMATOLOGY

He is a passionate and dedicated leader in the oncology clinical research space with 20 years supporting biotech companies in their development of oncology treatments from proof-of-concept to commercialization. During his tenure at Worldwide, he has built a track record of delivering oncology study requirements on time or ahead of schedule. Alaeddin blends operational expertise and passion for patients. His robust oncology portfolio includes research work with metastatic breast cancer, prostate cancer, GIST, glioblastoma, early-phase solid tumors, and more. His passion for oncology extends back to his undergraduate studies, working with p53 and apoptosis of breast cancer cells in athymic mice, and it has grown into a lifelong career in cell and cancer biology. Alaeddin serves on Worldwide’s oncology leadership team.

JANA KNEZEVIC

SENIOR ONCOLOGY PROJECT MANAGER

Jana has more than a decade of experience in oncology therapeutic development, providing clinical trial management expertise with a strong grounding in regulatory affairs. With a background in CROs, sponsor companies, and academia, her knowledge spans the entire breadth of the clinical development space. Her personal dedication to therapeutic advancement in the service of cancer patients drives her commitment to supporting sponsors in their development goals.

LEANNE DRUMMOND

SENIOR DIRECTOR, PROJECT MANAGEMENT, ONCOLOGY AND RARE DISEASES

Leanne has more than 25 years of project management experience in CROs and the pharmaceutical industry, specializing in oncology studies. She is skilled in providing support and oversight to Worldwide’s large national and global project and program management teams. She mentors staff and assesses program metrics to ensure quality, time, and budget deliverables are met. She has supported all research stages, including CMC, pharmacology, toxicology, regulatory, and clinical studies phase I-IV, and has worked on more than 10 multi-indication development programs. Her therapeutic experience in oncology includes solid tumors, ovarian cancer, hematological malignancies, acute myeloid leukemia (requiring stem cell transplant, peripheral, and cord blood), breast cancer, and glioblastoma.

  • expert image
  • expert image
  • expert image

Expertise You Can Rely On 

We’ve cultivated a tenured, talented team of experts to craft unique, resourceful solutions for each and every project. Forge a partnership that matters and let Worldwide Clinical Trials Oncology introduce you to the research experience you deserve.

Oncology Experience

  • Common Cancers
  • Advanced Solid Tumors
  • Breast Cancer
  • Cervical Cancer
  • Chemo Induced Anorexia or Cachexia
  • Colorectal Cancer
  • Endometrial Cancer
  • Melanoma
  • Myelodysplastic Syndrome
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Stomach Cancer
  • Tenosynovial Giant Cell Tumor
  • Rare Cancers
  • Acute Myeloid Leukemia (AML)
  • B-Cell Non-Hodgkin Lymphoma
  • Cutaneous T-Cell Lymphoma
  • Gastrointestinal Stromal Tumor (GIST)
  • Glioblastoma Multiforme (GBM)
  • Hepatocellular Carcinoma
  • Idiopathic Thrombocytopenic Purpura
  • Triple-Negative Breast Cancer
  • Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Our Dedicated Team